TrialLancet (London, England)2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Kristin K Jørgensen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.